GSK's shingles vaccine threatens Merck/Sanofi's Zostavax
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has positive Phase III data from a trial of its shingles vaccine, which could threaten l Sanofi Pasteur MSD's (SPMSD) Zostavax, currently the only approved shingles vaccine on the market.